Literature DB >> 1660151

Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex.

D H Katz1, J F Marcelletti, M H Khalil, L E Pope, L R Katz.   

Abstract

This article reports that 1-docosanol, a 22-carbon-long saturated alcohol, exerts a substantial inhibitory effect on replication of certain viruses (e.g., herpes simplex virus and respiratory syncytial virus) within primary target cells in vitro. To study the basis for its viral inhibitory activity, a suspension of 1-docosanol was formulated in an inert and nontoxic surfactant, Pluronic F-68; this suspension exerted potent inhibitory activity on the ability of susceptible viruses to infect cultured target cells. Susceptible viruses included wild-type herpes simplex viruses 1 and 2 as well as acyclovir-resistant herpes simplex virus 2 and also respiratory syncytial virus--all of which are lipid-enveloped. In contrast, nonenveloped poliovirus was not susceptible to the inhibitory action of 1-docosanol. Although the precise mechanism has yet to be defined, current evidence suggests that 1-docosanol inhibits viral replication by interfering with the early intracellular events surrounding viral entry into target cells. It is possible that interaction between the highly lipophilic compound and components of target cell membranes renders such target cells less susceptible to viral fusion and/or entry. If this mechanism proves to be correct, 1-docosanol may provide a broad spectrum activity against many different viruses, especially those with lipid-containing envelopes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1660151      PMCID: PMC53024          DOI: 10.1073/pnas.88.23.10825

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  10 in total

1.  Chemotherapy: antiviral agents come of age.

Authors:  T H Maugh
Journal:  Science       Date:  1976-04-09       Impact factor: 47.728

2.  Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome.

Authors:  K S Erlich; J Mills; P Chatis; G J Mertz; D F Busch; S E Follansbee; R M Grant; C S Crumpacker
Journal:  N Engl J Med       Date:  1989-02-02       Impact factor: 91.245

3.  Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome.

Authors:  P A Chatis; C H Miller; L E Schrager; C S Crumpacker
Journal:  N Engl J Med       Date:  1989-02-02       Impact factor: 91.245

4.  Extreme sensitivity of enveloped viruses, including herpes simplex, to long-chain unsaturated monoglycerides and alcohols.

Authors:  J Sands; D Auperin; W Snipes
Journal:  Antimicrob Agents Chemother       Date:  1979-01       Impact factor: 5.191

5.  Electron microscopy of herpes simplex virus. I. Entry.

Authors:  C Morgan; H M Rose; B Mednis
Journal:  J Virol       Date:  1968-05       Impact factor: 5.103

6.  Monoclonal antibodies to herpes simplex virus type 1 proteins, including the immediate-early protein ICP 4.

Authors:  S D Showalter; M Zweig; B Hampar
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

7.  Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data.

Authors:  S Safrin; T Assaykeen; S Follansbee; J Mills
Journal:  J Infect Dis       Date:  1990-06       Impact factor: 5.226

8.  Evaluation of triacontanol-containing compounds as anti-inflammatory agents using guinea pig models.

Authors:  P T McBride; L Clark; G G Krueger
Journal:  J Invest Dermatol       Date:  1987-10       Impact factor: 8.551

9.  Inactivation of lipid-containing viruses by long-chain alcohols.

Authors:  W Snipes; S Person; G Keller; W Taylor; A Keith
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

10.  Solid-phase enzyme-immunoassay for the detection of herpes simplex virus antigens in clinical specimens.

Authors:  T Ziegler; O H Meurman; P P Arstila; P E Halonen
Journal:  J Virol Methods       Date:  1983-07       Impact factor: 2.014

  10 in total
  13 in total

Review 1.  How were new medicines discovered?

Authors:  David C Swinney; Jason Anthony
Journal:  Nat Rev Drug Discov       Date:  2011-06-24       Impact factor: 84.694

Review 2.  The discovery of first-in-class drugs: origins and evolution.

Authors:  Jörg Eder; Richard Sedrani; Christian Wiesmann
Journal:  Nat Rev Drug Discov       Date:  2014-07-18       Impact factor: 84.694

Review 3.  Approved Antiviral Drugs over the Past 50 Years.

Authors:  Erik De Clercq; Guangdi Li
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

4.  Discovery of Small-Molecule Inhibitors Targeting the E3 Ubiquitin Ligase Activity of the Herpes Simplex Virus 1 ICP0 Protein Using an In Vitro High-Throughput Screening Assay.

Authors:  Thibaut Deschamps; Hope Waisner; Christos Dogrammatzis; Anuradha Roy; Shibin Chacko; Chamani Perera; Thomas E Prisinzano; Maria Kalamvoki
Journal:  J Virol       Date:  2019-06-14       Impact factor: 5.103

5.  Structural parameters governing activity of Pluronic triblock copolymers in hyperthermia cancer therapy.

Authors:  Tianyi M Krupka; Agata A Exner
Journal:  Int J Hyperthermia       Date:  2011       Impact factor: 3.914

Review 6.  Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeutics.

Authors:  Thessicar E Antoine; Paul J Park; Deepak Shukla
Journal:  Rev Med Virol       Date:  2013-02-26       Impact factor: 6.989

7.  GM-144, a novel lipophilic vaginal contraceptive gel-microemulsion.

Authors:  O J D'Cruz; S H Yiv; F M Uckun
Journal:  AAPS PharmSciTech       Date:  2001-04-09       Impact factor: 3.246

Review 8.  New antiherpesvirus agents. Their targets and therapeutic potential.

Authors:  F A Alrabiah; S L Sacks
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

Review 9.  New antiviral agents.

Authors:  Nahed Abdel-Haq; Pimpanada Chearskul; Hossam Al-Tatari; Basim Asmar
Journal:  Indian J Pediatr       Date:  2006-04       Impact factor: 5.319

10.  Isolation and characterization of the compounds responsible for the antimutagenic activity of Combretum microphyllum (Combretaceae) leaf extracts.

Authors:  Tshepiso Jan Makhafola; Esameldin Elzein Elgorashi; Lyndy Joy McGaw; Maurice Ducret Awouafack; Luc Verschaeve; Jacobus Nicolaas Eloff
Journal:  BMC Complement Altern Med       Date:  2017-09-06       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.